Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ASLAN Pharma and ACT Genomics to Collaborate

publication date: Jul 8, 2015
ASLAN Pharmaceuticals, a Singapore clinical-stage biopharma, will collaborate with ACT Genomics of Taiwan to undertake detailed genomic studies of patients who exhibit better-than-expected therapeutic responses to a given therapy. As an example, in a clinical trial of ASLAN001, one patient with bile duct cancer experienced an 87% shrinkage in the tumor, a very positive reaction in a type of cancer that is difficult to treat. ACT is combining next-gen sequencing and multiplex molecular testing platforms to develop clinical molecule assays. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital